Compare Bristol-Myers Squibb Co (BMY) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Impinj Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B), while Impinj Inc trades at $175.27 (market cap $5.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 24.6× Impinj Inc's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| BMY | PI | |
|---|---|---|
Market Cap | $132.45B | $5.38B |
Sector | Health | Technology |
52-Week High | $65.89 | $241.91 |
52-Week Low | $42.60 | $91.34 |
Enterprise Value | $166.44B | $5.52B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Impinj (PI) trades at $183.36, up 6.66% in 24 hours, showing strong momentum after Q2 2026 earnings beat with record revenue and EPS of $0.86 versus $0.81 expected. Technical indicators signal bullish momentum with the stock above key moving averages, though RSI levels suggest overbought conditions. The company maintains solid gross margins of 52.86% but faces profitability challenges with negative net income margins and ROE.
While analyst consensus remains strongly bullish with a $186 price target and institutional buying interest, investors should weigh the stock's premium valuation (P/S 14.26) against ongoing profitability concerns and recent insider selling activity. The company's specialized RAIN RFID technology positions it for growth in retail and supply chain markets, but execution risks and competitive pressures remain key considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
